argenx

Halozyme announces FDA approval for Roche's Tecentriq Hybreza™, a subcutaneous anti-PD-(L)1 immunotherapy using ENHANZE® technology, offering faster administration and broader treatment options for lung, liver, skin, and soft tissue cancers.

FDA approves Roche's Tecentriq Hybreza™, a subcutaneous anti-PD-(L)1 immunotherapy using Halozyme's ENHANZE® technology, reducing injection time to 7 minutes from 30-60 minutes for IV infusion, available for adult indications of IV Tecentriq® in the U.S.

Ursula von der Leyen commits to a 2025 Biotech Act; Flanders Institute of Biotechnology calls for a biotech coalition of member states. Europe challenges US dominance in scientific research, but lacks sufficient support systems for start-ups. Europe faces a funding shortfall fivefold that of the US, with biotech firms often choosing American IPOs. Regulatory approval in Europe is slower than the FDA, delaying innovation and therapy delivery. A 'Coalition of the Willing Member States' is proposed to streamline biotech progress, addressing regulatory and financial challenges.